JP2020522473A - Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 - Google Patents
Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 Download PDFInfo
- Publication number
- JP2020522473A JP2020522473A JP2019564917A JP2019564917A JP2020522473A JP 2020522473 A JP2020522473 A JP 2020522473A JP 2019564917 A JP2019564917 A JP 2019564917A JP 2019564917 A JP2019564917 A JP 2019564917A JP 2020522473 A JP2020522473 A JP 2020522473A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable domain
- binding site
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 278
- 108091007433 antigens Proteins 0.000 title claims abstract description 278
- 102000036639 antigens Human genes 0.000 title claims abstract description 278
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 139
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 title claims abstract description 132
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 131
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 130
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 title claims abstract description 121
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 title claims abstract description 36
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 title claims abstract description 36
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 title claims abstract description 22
- 230000027455 binding Effects 0.000 claims abstract description 356
- 210000000822 natural killer cell Anatomy 0.000 claims abstract description 95
- 201000011510 cancer Diseases 0.000 claims abstract description 75
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims abstract description 66
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims abstract description 66
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims abstract description 48
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims abstract description 47
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims abstract description 45
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims abstract description 45
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims abstract description 45
- 102100040120 Prominin-1 Human genes 0.000 claims abstract description 45
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims abstract description 43
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims abstract description 43
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims abstract description 42
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims abstract description 41
- 108010065524 CD52 Antigen Proteins 0.000 claims abstract description 7
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims abstract 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 231
- 210000004027 cell Anatomy 0.000 claims description 142
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 74
- 241000282414 Homo sapiens Species 0.000 claims description 63
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 61
- 229920001184 polypeptide Polymers 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 49
- 238000009472 formulation Methods 0.000 claims description 38
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 32
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 28
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 28
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 27
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 26
- 230000036210 malignancy Effects 0.000 claims description 19
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 16
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 16
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 16
- 201000003444 follicular lymphoma Diseases 0.000 claims description 16
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 16
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 14
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 208000017604 Hodgkin disease Diseases 0.000 claims description 11
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 11
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 11
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 11
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 11
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 10
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 10
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 10
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 10
- 201000005962 mycosis fungoides Diseases 0.000 claims description 10
- 239000001608 potassium adipate Substances 0.000 claims description 10
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 10
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims description 8
- 102000044042 human KLRK1 Human genes 0.000 claims description 8
- 206010001413 Adult T-cell lymphoma/leukaemia Diseases 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 208000034578 Multiple myelomas Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 206010009944 Colon cancer Diseases 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 208000005017 glioblastoma Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000032612 Glial tumor Diseases 0.000 claims description 5
- 206010018338 Glioma Diseases 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 5
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 5
- 201000000331 Testicular germ cell cancer Diseases 0.000 claims description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 5
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 208000008732 thymoma Diseases 0.000 claims description 5
- 206010046766 uterine cancer Diseases 0.000 claims description 5
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 239000001601 sodium adipate Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000001605 fetal effect Effects 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 230000030833 cell death Effects 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 108091008324 binding proteins Proteins 0.000 abstract description 59
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 11
- 102000005962 receptors Human genes 0.000 abstract description 11
- 108020003175 receptors Proteins 0.000 abstract description 11
- 230000003213 activating effect Effects 0.000 abstract description 8
- 239000003446 ligand Substances 0.000 abstract description 8
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 abstract description 4
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 abstract description 4
- 241000282567 Macaca fascicularis Species 0.000 abstract description 3
- 241000283984 Rodentia Species 0.000 abstract description 2
- 241000894007 species Species 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- 102000023732 binding proteins Human genes 0.000 abstract 2
- 235000018102 proteins Nutrition 0.000 description 59
- 102000014914 Carrier Proteins Human genes 0.000 description 57
- 230000037396 body weight Effects 0.000 description 46
- 238000006467 substitution reaction Methods 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 25
- 108010074328 Interferon-gamma Proteins 0.000 description 21
- 102100037850 Interferon gamma Human genes 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 230000004913 activation Effects 0.000 description 20
- 230000035772 mutation Effects 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 18
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 18
- -1 NCR Proteins 0.000 description 17
- 239000012669 liquid formulation Substances 0.000 description 16
- 230000008685 targeting Effects 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000010586 diagram Methods 0.000 description 14
- 239000000833 heterodimer Substances 0.000 description 14
- 238000005734 heterodimerization reaction Methods 0.000 description 14
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 13
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 150000003839 salts Chemical class 0.000 description 13
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 12
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 239000002585 base Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000009089 cytolysis Effects 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 206010025323 Lymphomas Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 229960002685 biotin Drugs 0.000 description 9
- 239000011616 biotin Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000001963 growth medium Substances 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 208000003950 B-cell lymphoma Diseases 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 8
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 229930195725 Mannitol Natural products 0.000 description 8
- 101100404853 Mus musculus Klrk1 gene Proteins 0.000 description 8
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 8
- 150000007513 acids Chemical class 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 8
- 231100000135 cytotoxicity Toxicity 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000594 mannitol Substances 0.000 description 8
- 235000010355 mannitol Nutrition 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000008227 sterile water for injection Substances 0.000 description 8
- 230000006051 NK cell activation Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000006240 deamidation Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 230000009870 specific binding Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 239000008365 aqueous carrier Substances 0.000 description 6
- 239000008228 bacteriostatic water for injection Substances 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 229940126534 drug product Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000000825 pharmaceutical preparation Substances 0.000 description 6
- 229920005862 polyol Polymers 0.000 description 6
- 150000003077 polyols Chemical class 0.000 description 6
- 229960003857 proglumide Drugs 0.000 description 6
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 101710145634 Antigen 1 Proteins 0.000 description 5
- 108020003285 Isocitrate lyase Proteins 0.000 description 5
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 5
- 229930191564 Monensin Natural products 0.000 description 5
- GAOZTHIDHYLHMS-UHFFFAOYSA-N Monensin A Natural products O1C(CC)(C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CCC1C(O1)(C)CCC21CC(O)C(C)C(C(C)C(OC)C(C)C(O)=O)O2 GAOZTHIDHYLHMS-UHFFFAOYSA-N 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 208000009956 adenocarcinoma Diseases 0.000 description 5
- KQNZDYYTLMIZCT-KQPMLPITSA-N brefeldin A Chemical compound O[C@@H]1\C=C\C(=O)O[C@@H](C)CCC\C=C\[C@@H]2C[C@H](O)C[C@H]21 KQNZDYYTLMIZCT-KQPMLPITSA-N 0.000 description 5
- 239000004067 bulking agent Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000010445 mica Substances 0.000 description 5
- 229910052618 mica group Inorganic materials 0.000 description 5
- 229960005358 monensin Drugs 0.000 description 5
- GAOZTHIDHYLHMS-KEOBGNEYSA-N monensin A Chemical compound C([C@@](O1)(C)[C@H]2CC[C@@](O2)(CC)[C@H]2[C@H](C[C@@H](O2)[C@@H]2[C@H](C[C@@H](C)[C@](O)(CO)O2)C)C)C[C@@]21C[C@H](O)[C@@H](C)[C@@H]([C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O2 GAOZTHIDHYLHMS-KEOBGNEYSA-N 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229960004641 rituximab Drugs 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 description 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 206010042971 T-cell lymphoma Diseases 0.000 description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- JUMGSHROWPPKFX-UHFFFAOYSA-N brefeldin-A Natural products CC1CCCC=CC2(C)CC(O)CC2(C)C(O)C=CC(=O)O1 JUMGSHROWPPKFX-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000710 homodimer Substances 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 239000012931 lyophilized formulation Substances 0.000 description 4
- 210000003519 mature b lymphocyte Anatomy 0.000 description 4
- 230000009871 nonspecific binding Effects 0.000 description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
- 229940068968 polysorbate 80 Drugs 0.000 description 4
- 230000018883 protein targeting Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000000284 resting effect Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 101100355609 Caenorhabditis elegans rae-1 gene Proteins 0.000 description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000033759 Prolymphocytic T-Cell Leukemia Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000026651 T-cell prolymphocytic leukemia Diseases 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229960004106 citric acid Drugs 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 238000000432 density-gradient centrifugation Methods 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- KDQPSPMLNJTZAL-UHFFFAOYSA-L disodium hydrogenphosphate dihydrate Chemical compound O.O.[Na+].[Na+].OP([O-])([O-])=O KDQPSPMLNJTZAL-UHFFFAOYSA-L 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 208000000649 small cell carcinoma Diseases 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- 229960002317 succinimide Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010061424 Anal cancer Diseases 0.000 description 2
- 108091008875 B cell receptors Proteins 0.000 description 2
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 description 2
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 2
- 229940126289 DNA-PK inhibitor Drugs 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 108010087819 Fc receptors Proteins 0.000 description 2
- 102000009109 Fc receptors Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- 102000002698 KIR Receptors Human genes 0.000 description 2
- 108010043610 KIR Receptors Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 101100174574 Mus musculus Pikfyve gene Proteins 0.000 description 2
- 208000002231 Muscle Neoplasms Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 206010054184 Small intestine carcinoma Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000013011 aqueous formulation Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000006491 bone marrow cancer Diseases 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 238000002619 cancer immunotherapy Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002022 differential scanning fluorescence spectroscopy Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 2
- 208000021937 marginal zone lymphoma Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000002077 muscle cancer Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003973 paint Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 150000003890 succinate salts Chemical class 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108010005465 AC133 Antigen Proteins 0.000 description 1
- 102000005908 AC133 Antigen Human genes 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 208000012526 B-cell neoplasm Diseases 0.000 description 1
- 229940124290 BCR-ABL tyrosine kinase inhibitor Drugs 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229940125814 BTK kinase inhibitor Drugs 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 102100038077 CD226 antigen Human genes 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102000013135 CD52 Antigen Human genes 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 239000012275 CTLA-4 inhibitor Substances 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- 102100034744 Cell division cycle 7-related protein kinase Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 208000004378 Choroid plexus papilloma Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 102100032768 Complement receptor type 2 Human genes 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 1
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061825 Duodenal neoplasm Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000003693 Hedgehog Proteins Human genes 0.000 description 1
- 108090000031 Hedgehog Proteins Proteins 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 206010073073 Hepatobiliary cancer Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 101000945740 Homo sapiens Cell division cycle 7-related protein kinase Proteins 0.000 description 1
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 1
- 101000744394 Homo sapiens Oxidized purine nucleoside triphosphate hydrolase Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101100101727 Homo sapiens RAET1L gene Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 description 1
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 description 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 description 1
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 108010044023 Ki-1 Antigen Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 102000017578 LAG3 Human genes 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 229940124787 MELK inhibitor Drugs 0.000 description 1
- 101100404851 Macaca fascicularis KLRK1 gene Proteins 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025537 Malignant anorectal neoplasms Diseases 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 description 1
- 208000015021 Meningeal Neoplasms Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028729 Nasal cavity cancer Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 description 1
- 206010029488 Nodular melanoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100039792 Oxidized purine nucleoside triphosphate hydrolase Human genes 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000037064 Papilloma of choroid plexus Diseases 0.000 description 1
- 206010061336 Pelvic neoplasm Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 229920002123 Pentastarch Polymers 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 1
- 208000033766 Prolymphocytic Leukemia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 206010051807 Pseudosarcoma Diseases 0.000 description 1
- 201000008183 Pulmonary blastoma Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000010502 Subcutaneous panniculitis-like T-cell lymphoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000025317 T-cell and NK-cell neoplasm Diseases 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108700031126 Tetraspanins Proteins 0.000 description 1
- 102000043977 Tetraspanins Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 206010062129 Tongue neoplasm Diseases 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 description 1
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 description 1
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 description 1
- 102100040013 UL16-binding protein 6 Human genes 0.000 description 1
- 101150013568 US16 gene Proteins 0.000 description 1
- 208000023915 Ureteral Neoplasms Diseases 0.000 description 1
- 206010046392 Ureteric cancer Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 229940124674 VEGF-R inhibitor Drugs 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- ZVNYJIZDIRKMBF-UHFFFAOYSA-N Vesnarinone Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)N1CCN(C=2C=C3CCC(=O)NC3=CC=2)CC1 ZVNYJIZDIRKMBF-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000012018 Yolk sac tumor Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000001256 adenosarcoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 201000007696 anal canal cancer Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 206010002449 angioimmunoblastic T-cell lymphoma Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 201000009036 biliary tract cancer Diseases 0.000 description 1
- 208000020790 biliary tract neoplasm Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001754 blood buffy coat Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 208000002458 carcinoid tumor Diseases 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 description 1
- 229960003230 cetrorelix Drugs 0.000 description 1
- 108700008462 cetrorelix Proteins 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 201000010918 connective tissue cancer Diseases 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- BALGDZWGNCXXES-UHFFFAOYSA-N cyclopentane;propanoic acid Chemical compound CCC(O)=O.C1CCCC1 BALGDZWGNCXXES-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011118 depth filtration Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 201000000312 duodenum cancer Diseases 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 208000001991 endodermal sinus tumor Diseases 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 201000006828 endometrial hyperplasia Diseases 0.000 description 1
- 201000000330 endometrial stromal sarcoma Diseases 0.000 description 1
- 208000029179 endometrioid stromal sarcoma Diseases 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 229960002199 etretinate Drugs 0.000 description 1
- HQMNCQVAMBCHCO-DJRRULDNSA-N etretinate Chemical compound CCOC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=C(OC)C(C)=C1C HQMNCQVAMBCHCO-DJRRULDNSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 210000000285 follicular dendritic cell Anatomy 0.000 description 1
- 229960004421 formestane Drugs 0.000 description 1
- OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- 150000002411 histidines Chemical class 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- 201000002312 ileal neoplasm Diseases 0.000 description 1
- 210000003297 immature b lymphocyte Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010212 intracellular staining Methods 0.000 description 1
- 208000020082 intraepithelial neoplasia Diseases 0.000 description 1
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 201000003856 jejunal cancer Diseases 0.000 description 1
- 201000009592 jejunal neoplasm Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 201000005831 male reproductive organ cancer Diseases 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000006178 malignant mesothelioma Diseases 0.000 description 1
- 208000022006 malignant tumor of meninges Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000008203 medulloepithelioma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000012434 mixed-mode chromatography Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 201000011682 nervous system cancer Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- YMVWGSQGCWCDGW-UHFFFAOYSA-N nitracrine Chemical compound C1=CC([N+]([O-])=O)=C2C(NCCCN(C)C)=C(C=CC=C3)C3=NC2=C1 YMVWGSQGCWCDGW-UHFFFAOYSA-N 0.000 description 1
- 229950008607 nitracrine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 201000000032 nodular malignant melanoma Diseases 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 201000000890 orbital cancer Diseases 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940023569 palmate Drugs 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000002974 pharmacogenomic effect Effects 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical class CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000003728 serous cell Anatomy 0.000 description 1
- 208000037968 sinus cancer Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 201000000267 smooth muscle cancer Diseases 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 201000011096 spinal cancer Diseases 0.000 description 1
- 208000014618 spinal cord cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003567 thiocyanates Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical class CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 201000011294 ureter cancer Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 229950005577 vesnarinone Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464424—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2893—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD52
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
本出願は、2017年5月23日に出願された米国仮特許出願番号第62/510,173号、2017年7月31日に出願された米国仮特許出願番号第62/539,396号、2017年7月31日に出願された米国仮特許出願番号第62/539,416号、2017年7月31日に出願された米国仮特許出願番号第62/539,419号、2017年8月16日に出願された米国仮特許出願番号第62/546,292号、2017年8月16日に出願された米国仮特許出願番号第62/546,296号、および2017年8月30日に出願された米国仮特許出願番号第62/552,146号に基づく利益および優先権を主張し、これらのそれぞれの全体の内容は、すべての目的のために本明細書中に参考として援用される。
本出願は、ASCIIフォーマットで電子提出された配列表を含み、その全体は、参照により本明細書に組み込まれている。前記ASCIIコピーは2018年5月21日に作成され、DFY−022WO.txtという名称であり、212kbのサイズである。
本発明は、NKG2D、CD16、およびCD37、CD20、CD19、CD22、CD30、CD52およびCD133から選択される腫瘍関連抗原に結合する多重特異性結合タンパク質に関する。
がんは、この疾患を処置するための文献に報告されている十分な研究努力および科学進歩にもかかわらず、重大な健康問題であり続けている。血液および骨髄のがんは、頻繁に診断されるがんの種類である(多発性骨髄腫、白血病、およびリンパ腫が挙げられる)。これらのがんに対する現在の処置選択肢は、すべての患者に効果的というわけではなく、および/または実質的な有害副作用を有する可能性がある。他の種類のがんも、既存の治療選択肢を使用して処置することが依然として困難である。
CD133は、ヒト造血幹細胞および前駆細胞において主に同定される5回膜貫通糖タンパク質(pentaspan transmembrane glycoprotein)である。現在は、この表面受容体の生理学的役割は未知のままである。しかし、CD133は、種々の癌(乳がん、結腸がん、前立腺がん、肝臓がん、膵臓がん、肺がん、卵巣がん、腎臓がん、子宮がんおよび精巣胚細胞がん、急性骨髄性白血病、急性リンパ芽球性白血病、神経膠腫、膠芽腫ならびに頭頚部の扁平上皮癌が挙げられる)においてがん幹細胞のマーカーとして同定された。CD133は、p85と相互作用して、がん幹細胞においてPI3K/AKT/mTORシグナル伝達経路を活性化し得、この活性化は、その結果として、がん幹細胞を刺激して、腫瘍形成能力を促進させる。
本発明は、ナチュラルキラー細胞におけるNKG2D受容体およびCD16受容体、ならびにCD37、CD20、CD19、CD22、CD30、CD52およびCD133から選択される腫瘍関連抗原に結合する多重特異性結合タンパク質を提供する。かかるタンパク質は2種類以上のNK活性化受容体と会合することができ、天然リガンドのNKG2Dへの結合を阻止し得る。ある特定の実施形態では、タンパク質は、ヒトにおいてNK細胞を刺激し得る。一部の実施形態では、タンパク質は、ヒトならびにげっ歯動物およびカニクイザルなどの他の種においてNK細胞を刺激し得る。本発明の様々な態様および実施形態を以下にさらに詳細に記載する。
代替的に、CD19に結合する第2の抗原結合部位は、必要に応じて、配列番号199に関連する重鎖可変ドメインと、配列番号203に関連する軽鎖可変ドメインとを組み込んでいてもよい。例えば、第2の抗原結合部位の重鎖可変ドメインは、配列番号199と少なくとも90%(例えば、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、または100%)同一であり、かつ/または配列番号199のCDR1(配列番号200)、CDR2(配列番号201)、およびCDR3(配列番号202)配列と同一のアミノ酸配列を組み込んでいてもよい。同様に、第2の抗原結合部位の軽鎖可変ドメインは、配列番号203と少なくとも90%(例えば、90%、91%、92%、93%、94%、95%、96%、97%、98%、99%、または100%)同一であり、かつ/または配列番号203のCDR1(配列番号204)、CDR2(配列番号205)、およびCDR3(配列番号206)配列と同一のアミノ酸配列を組み込んでいてもよい。
本発明は、ナチュラルキラー細胞上のNKG2D受容体およびCD16受容体、ならびにCD37、CD20、CD19、CD22、CD30、CD52およびCD133から選択される腫瘍関連抗原に結合する多重特異性結合タンパク質を提供する。一部の実施形態では、多重特異性タンパク質はさらに、腫瘍関連抗原に結合するさらなる抗原結合部位を含む。本発明は、かかる多重特異性結合タンパク質を含む医薬組成物、ならびに、がんの処置などの目的のためのかかる多重特異性タンパク質および医薬組成物を使用する治療方法も提供する。本発明の様々な態様を複数のセクションに分けて以下に記述する。しかしながら、1つの特定のセクションに記載される本発明の態様は、いずれかの特定のセクションに限定されるものではない。
I.タンパク質
II.多重特異性タンパク質の特徴
III.治療用途
IV.併用療法
V.医薬組成物
(実施例1)
NKG2D結合ドメインはNKG2Dに結合する
NKG2D結合ドメインは精製した組換えNKG2Dに結合する
NKG2D結合ドメインはNKG2Dを発現する細胞に結合する
(実施例2)
NKG2D結合ドメインはNKG2Dへの天然リガンドの結合を阻止する
ULBP−6との競合
Rae−1デルタとの競合
(実施例3)
NKG2D結合ドメインクローンはNKG2Dを活性化させる
(実施例4)
NKG2D結合ドメインはNK細胞を活性化させる
初代ヒトNK細胞
初代マウスNK細胞
(実施例5)
NKG2D結合ドメインは標的腫瘍細胞の細胞傷害性を可能にする
NKG2D抗体は高い熱安定性を示す
(実施例7)
NKG2DおよびCD16の架橋によるヒトNK細胞の相乗的活性化
初代ヒトNK細胞活性化アッセイ
EL4マウスリンパ腫細胞株を、ヒトNKG2Dを発現するように工学操作した。NKG2D結合ドメイン、腫瘍関連抗原結合ドメイン(例えば、CD20結合ドメイン)および図1に示されるとおりのCD16に結合するFcドメインを各々含む三重特異的結合タンパク質(TriNKET)を、EL4細胞上で発現される細胞外NKG2Dに対するそれらの親和性について試験した。TriNKETを、20μg/mLに希釈し、次いで、段階希釈した。NKG2DへのTriNKETの結合を、フルオロフォアコンジュゲート抗ヒトIgG二次抗体を使用して検出した。次いで、細胞をフローサイトメトリーによって分析し、ヒストグラムをプロットした。試験したTriNKETとしては、CD26−TriNKET−CD20(クローンADI−28226に由来するNKG2D結合ドメインおよびリツキシマブに由来するCD20結合ドメイン)、およびF04−TriNKET−CD20(クローンADI−29404に由来するNKG2D結合ドメインおよびリツキシマブに由来するCD20結合ドメイン)が挙げられる。CD26−TriNKET−CD20の結合プロファイル(破線)、およびF04−TriNKET−CD20の結合プロファイル(実線)は、染色されていないサンプルと一緒に、図35に示される。その結果は、クローンADI−28226およびADI−29404による異なるレベルのNKG2Dへの結合を示す。
CD20を発現するRajiヒトリンパ腫細胞を使用して、腫瘍関連抗原CD20へのTriNKETの結合をアッセイした。TriNKETをその細胞とともにインキュベートし、その結合を、フルオロフォアコンジュゲート抗ヒトIgG二次抗体を使用して検出した。細胞をフローサイトメトリーによって分析し、ヒストグラムをプロットした。図36に示されるように、F04−TriNKET−CD20およびCD26−TriNKET−CD20は、CD20に等しく十分に結合する。
末梢血単核細胞(PBMC)を、密度勾配遠心分離を使用してヒト末梢血バフィコートから単離した。NK細胞(CD3− CD56+)を、PBMCから磁性ビーズでの陰性選択を使用して単離し、その単離したNK細胞の純度は、代表的には>90%であった。単離されたNK細胞を、活性化に関して100ng/mL IL−2を含む培地中で培養したか、またはサイトカインなしで一晩休止させた。IL−2活性化NK細胞を、活性化後の24〜48時間以内に使用した。休止NK細胞は常に、精製後に同日に使用した。
ヒトNK細胞がTriNKETの存在下でがん細胞を溶解する能力を試験するために、ヒトCD16a−158vを発現するように形質導入したヒトNK細胞株KHYG−1細胞を、エフェクター細胞として使用した。全ての細胞傷害性アッセイを、以下のとおりに調製した:目的の標的を発現するヒトがん細胞株(例えば、CD20陽性Raji細胞)を培養物から採取し、細胞をPBSで洗浄し、BATDA試薬(Perkin Elmer AD0116)で標識するために106/mLにおいて成長培地中で再懸濁した。標的細胞の標識を、製造業者の指示に倣った。標識後に、細胞をPBSで3回洗浄し、培養培地中で0.5〜1.0×105/mLで再懸濁した。バックグラウンドウェルを調製するために、その標識した細胞のアリコートをとっておき、その細胞を培地からスピンアウトした。その培地100μlを、三連でウェルへと注意深く添加して、ペレット化した細胞が乱れるのを回避した。BATDA標識細胞100μlを、96ウェルプレートの各ウェルに添加した。ウェルを、標的細胞からの自発的放出のために保全し、ウェルを、1% Triton−Xの添加による標的細胞の最大溶解のために調製した。目的の腫瘍標的に対するモノクローナル抗体またはTriNKETを、培養培地で希釈し、その希釈したモノクローナル抗体またはTriNKET50μlを、各ウェルに添加した。KHYG−1−CD16−158V細胞を洗浄し、所望のエフェクター細胞 対 標的細胞比に応じて、培養培地中に105〜2.0×106/mLで再懸濁した。NK細胞50μlを、そのプレートの各ウェルに添加して、合計200μl培養容積にした。そのプレートを、そのアッセイを展開する前に、37℃において5% CO2と2〜3時間にわたってインキュベートした。
参照による組み込み
等価物
Claims (66)
- (a)NKG2Dに結合する第1の抗原結合部位と、
(b)CD37、CD20、CD19、CD22、CD30、CD52またはCD133に結合する第2の抗原結合部位と、
(c)CD16に結合するに十分な抗体Fcドメインもしくはその一部分、またはCD16に結合する第3の抗原結合部位と
を含むタンパク質。 - 前記第1の抗原結合部位が、ヒトのNKG2Dに結合する、請求項1に記載のタンパク質。
- 前記第1の抗原結合部位が、重鎖可変ドメインおよび軽鎖可変ドメインを含む、請求項1または2に記載のタンパク質。
- 前記重鎖可変ドメインおよび前記軽鎖可変ドメインが、同じポリペプチド上に存在する、請求項3に記載のタンパク質。
- 前記第2の抗原結合部位が、重鎖可変ドメインおよび軽鎖可変ドメインを含む、請求項3または4に記載のタンパク質。
- 前記第2の抗原結合部位の前記重鎖可変ドメインおよび前記軽鎖可変ドメインが、同じポリペプチド上に存在する、請求項5に記載のタンパク質。
- 前記第1の抗原結合部位の前記軽鎖可変ドメインが、前記第2の抗原結合部位の前記軽鎖可変ドメインのアミノ酸配列と同一のアミノ酸配列を有する、請求項5または6に記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号1、配列番号41、配列番号49、配列番号57、配列番号59、配列番号61、配列番号69、配列番号77、配列番号85および配列番号93から選択されるアミノ酸配列と少なくとも90%同一の重鎖可変ドメインを含む、先行する請求項のいずれか一項に記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号41と少なくとも90%同一の重鎖可変ドメインと、配列番号42と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号49と少なくとも90%同一の重鎖可変ドメインと、配列番号50と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号57と少なくとも90%同一の重鎖可変ドメインと、配列番号58と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号59と少なくとも90%同一の重鎖可変ドメインと、配列番号60と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号61と少なくとも90%同一の重鎖可変ドメインと、配列番号62と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号69と少なくとも90%同一の重鎖可変ドメインと、配列番号70と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号77と少なくとも90%同一の重鎖可変ドメインと、配列番号78と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号85と少なくとも90%同一の重鎖可変ドメインと、配列番号86と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号93と少なくとも90%同一の重鎖可変ドメインと、配列番号94と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号101と少なくとも90%同一の重鎖可変ドメインと、配列番号102と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、配列番号103と少なくとも90%同一の重鎖可変ドメインと、配列番号104と少なくとも90%同一の軽鎖可変ドメインとを含む、請求項1から7のいずれかに記載のタンパク質。
- 前記第1の抗原結合部位が、単一ドメイン抗体である、請求項1または2に記載のタンパク質。
- 前記単一ドメイン抗体が、VHH断片またはVNAR断片である、請求項20に記載のタンパク質。
- 前記第2の抗原結合部位が、重鎖可変ドメインおよび軽鎖可変ドメインを含む、請求項1、2、または20から21のいずれか一項に記載のタンパク質。
- 前記第2の抗原結合部位の前記重鎖可変ドメインおよび前記軽鎖可変ドメインが、同じポリペプチド上に存在する、請求項22に記載のタンパク質。
- 前記第2の抗原結合部位は、CD37に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号109と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号113と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD37に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号117と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号121と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD37に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号125と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号129と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD20に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号134と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号138と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD20に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号142と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号146と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD20に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号150と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号154と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD20に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号158と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号162と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD20に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号166と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号170と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD19に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号175と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号179と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD19に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号183と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号187と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD19に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号191と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号195と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD19に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号199と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号203と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD22に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号208と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号212と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD22に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号216と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号220と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD22に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号224と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号228と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD30に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号233と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号237と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD30に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号241と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号245と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD30に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号249と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号253と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD30に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号257と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号261と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD30に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号265と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号269と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD52に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号274と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号278と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD52に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号282と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号286と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD133に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号291と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号295と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD133に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号299と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号303と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD133に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号307と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号311と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位は、CD133に結合し、前記第2の抗原結合部位の前記重鎖可変ドメインは、配列番号315と少なくとも90%同一のアミノ酸配列を含み、前記第2の抗原結合部位の前記軽鎖可変ドメインは、配列番号319と少なくとも90%同一のアミノ酸配列を含む、請求項1〜23のいずれか1項に記載のタンパク質。
- 前記第2の抗原結合部位が、単一ドメイン抗体である、請求項1から4または8から21のいずれか一項に記載のタンパク質。
- 前記第2の抗原結合部位が、VHH断片またはVNAR断片である、請求項50に記載のタンパク質。
- 前記タンパク質が、CD16に結合するに十分な抗体Fcドメインの一部分を含み、前記抗体Fcドメインが、ヒンジおよびCH2ドメインを含む、先行する請求項のいずれか一項に記載のタンパク質。
- 前記抗体Fcドメインが、ヒトIgG1抗体のヒンジおよびCH2ドメインを含む、請求項52に記載のタンパク質。
- 前記Fcドメインが、ヒトIgG1抗体のアミノ酸234〜332と少なくとも90%同一のアミノ酸配列を含む、請求項52または53に記載のタンパク質。
- 前記Fcドメインが、ヒトIgG1のFcドメインと少なくとも90%同一のアミノ酸配列を含み、Q347、Y349、L351、S354、E356、E357、K360、Q362、S364、T366、L368、K370、N390、K392、T394、D399、S400、D401、F405、Y407、K409、T411、K439からなる群から選択される1つまたは複数の位置において異なる、請求項54に記載のタンパク質。
- 先行する請求項のいずれか一項に記載のタンパク質および薬学的に許容される担体を含む製剤。
- 請求項1から55のいずれか一項に記載のタンパク質を発現する1つまたは複数の核酸を含む細胞。
- 有効量の、請求項1〜55のいずれか1項に記載のタンパク質に、腫瘍細胞およびナチュラルキラー細胞を曝露する工程を包含する、腫瘍細胞死を増強する方法。
- 有効量の、請求項1〜55のいずれか1項に記載のタンパク質または請求項56に記載の製剤を、患者に投与することを包含する、がんを処置する方法。
- 前記タンパク質の前記第2の抗原結合部位は、CD37に結合し、処置される前記がんは、B細胞性慢性リンパ性白血病(CLL)、ヘアリー細胞白血病(HCL)、非ホジキンリンパ腫、および急性骨髄性白血病からなる群より選択される、請求項59に記載の方法。
- 前記タンパク質の前記第2の抗原結合部位は、CD20に結合し、処置される前記がんは、慢性リンパ性白血病、非ホジキンリンパ腫、濾胞性リンパ腫、およびB細胞悪性腫瘍からなる群より選択される、請求項59に記載の方法。
- 前記タンパク質の前記第2の抗原結合部位は、CD19に結合し、処置される前記がんは、慢性リンパ性白血病、非ホジキンリンパ腫、濾胞性リンパ腫、急性リンパ芽球性白血病、B細胞悪性腫瘍、多発性骨髄腫、および急性骨髄性白血病からなる群より選択される、請求項59に記載の方法。
- 前記タンパク質の前記第2の抗原結合部位は、CD22に結合し、処置される前記がんは、慢性リンパ性白血病、非ホジキンリンパ腫、濾胞性リンパ腫、急性リンパ芽球性白血病、B細胞悪性腫瘍、およびヘアリー細胞白血病からなる群より選択される、請求項59に記載の方法。
- 前記タンパク質の前記第2の抗原結合部位は、CD30に結合し、処置される前記がんは、ホジキンリンパ腫、未分化大細胞リンパ腫、皮膚T細胞リンパ腫、末梢T細胞リンパ腫、成人T細胞白血病−リンパ腫、びまん性大細胞型B細胞リンパ腫、非ホジキンリンパ腫、および胎児性細胞癌からなる群より選択される、請求項59に記載の方法。
- 前記タンパク質の前記第2の抗原結合部位は、CD52に結合し、処置される前記がんは、慢性リンパ性白血病(CLL)、皮膚T細胞リンパ腫、末梢T細胞リンパ腫およびT細胞性前リンパ球性白血病、B細胞悪性腫瘍、非ホジキンリンパ腫、ホジキンリンパ腫、未分化大細胞リンパ腫、成人T細胞白血病−リンパ腫、成熟T/ナチュラルキラー(NK)細胞新生物、ならびに胸腺腫からなる群より選択される、請求項59に記載の方法。
- 前記タンパク質の前記第2の抗原結合部位は、CD133に結合し、処置される前記がんは、乳がん、結腸がん、前立腺がん、肝臓がん、膵臓がん、肺がん、卵巣がん、腎臓がん、子宮がん、精巣胚細胞がん、急性骨髄性白血病、急性リンパ芽球性白血病、神経膠腫、膠芽腫、および頭頚部の扁平上皮癌からなる群より選択される、請求項59に記載の方法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023172090A JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 |
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762510173P | 2017-05-23 | 2017-05-23 | |
US62/510,173 | 2017-05-23 | ||
US201762539419P | 2017-07-31 | 2017-07-31 | |
US201762539416P | 2017-07-31 | 2017-07-31 | |
US201762539396P | 2017-07-31 | 2017-07-31 | |
US62/539,419 | 2017-07-31 | ||
US62/539,416 | 2017-07-31 | ||
US62/539,396 | 2017-07-31 | ||
US201762546296P | 2017-08-16 | 2017-08-16 | |
US201762546292P | 2017-08-16 | 2017-08-16 | |
US62/546,296 | 2017-08-16 | ||
US62/546,292 | 2017-08-16 | ||
US201762552146P | 2017-08-30 | 2017-08-30 | |
US62/552,146 | 2017-08-30 | ||
PCT/US2018/034223 WO2018217947A1 (en) | 2017-05-23 | 2018-05-23 | A protein binding nkg2d, cd16 and a tumor-associated antigen |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023172090A Division JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020522473A true JP2020522473A (ja) | 2020-07-30 |
JP2020522473A5 JP2020522473A5 (ja) | 2021-07-26 |
Family
ID=64395887
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019564917A Pending JP2020522473A (ja) | 2017-05-23 | 2018-05-23 | Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 |
JP2023172090A Pending JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023172090A Pending JP2024012297A (ja) | 2017-05-23 | 2023-10-03 | Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20200157227A1 (ja) |
EP (1) | EP3630169A4 (ja) |
JP (2) | JP2020522473A (ja) |
KR (1) | KR20200010430A (ja) |
CN (1) | CN111278455A (ja) |
AU (1) | AU2018271930A1 (ja) |
BR (1) | BR112019024632A2 (ja) |
CA (1) | CA3064714A1 (ja) |
IL (1) | IL270803A (ja) |
MX (1) | MX2019014000A (ja) |
RU (1) | RU2019142715A (ja) |
WO (1) | WO2018217947A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
CN114555117A (zh) * | 2019-10-12 | 2022-05-27 | 百奥泰生物制药股份有限公司 | 抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用 |
CN114057875B (zh) * | 2020-07-31 | 2023-05-05 | 北京市神经外科研究所 | 抗cd133的单链抗体及其在制备治疗肿瘤的药物中的用途 |
PL244438B1 (pl) * | 2020-12-28 | 2024-01-29 | Inst Biochemii I Biofizyki Polskiej Akademii Nauk | Peptyd do stosowania w leczeniu lub zapobieganiu COVID-19 |
CN117580865A (zh) * | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011506406A (ja) * | 2007-12-14 | 2011-03-03 | ノボ・ノルデイスク・エー/エス | ヒトnkg2dに対する抗体とその使用 |
JP2013500721A (ja) * | 2009-07-29 | 2013-01-10 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
WO2015197598A2 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
WO2016207273A2 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific antigen binding proteins |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10261223A1 (de) * | 2002-12-20 | 2004-07-08 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Steigerung der Immunantwort durch Substanzen, welche die Funktion von Natürlichen Killerzellen beeinflussen |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
WO2011143545A1 (en) * | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
WO2012061558A2 (en) * | 2010-11-04 | 2012-05-10 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
LT2794658T (lt) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
US20140154253A1 (en) * | 2012-07-13 | 2014-06-05 | Zymeworks Inc. | Bispecific Asymmetric Heterodimers Comprising Anti-CD3 Constructs |
NZ630563A (en) * | 2012-09-27 | 2017-04-28 | Merus Nv | Bispecific igg antibodies as t cell engagers |
WO2015013671A1 (en) * | 2013-07-25 | 2015-01-29 | Cytomx Therapeutics, Inc. | Multispecific antibodies, multispecific activatable antibodies and methods of using the same |
CN106062206A (zh) * | 2014-01-15 | 2016-10-26 | 酵活有限公司 | 双特异性cd3和cd19抗原结合构建体 |
US20170022291A1 (en) * | 2014-04-01 | 2017-01-26 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
EP3148580B1 (en) * | 2014-05-29 | 2021-01-20 | MacroGenics, Inc. | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
TW201627322A (zh) * | 2015-01-26 | 2016-08-01 | 宏觀基因股份有限公司 | 抗-dr5抗體和包括其dr5-結合結構域的分子 |
CN107223135B (zh) * | 2015-03-16 | 2021-11-02 | 亥姆霍兹慕尼黑中心-德国环境健康研究中心(Gmbh) | 用于治疗hbv感染和相关病症的三特异性结合分子 |
EP3322735A4 (en) * | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | BISPECIFIC ANTIGEN-BINDING CONSTRUCTS CONJUGATED TO A MEDICINAL PRODUCT |
WO2017081190A1 (en) * | 2015-11-13 | 2017-05-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti- nkg2d single domain antibodies and uses thereof |
CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
-
2018
- 2018-05-23 CA CA3064714A patent/CA3064714A1/en active Pending
- 2018-05-23 CN CN201880051763.5A patent/CN111278455A/zh active Pending
- 2018-05-23 MX MX2019014000A patent/MX2019014000A/es unknown
- 2018-05-23 KR KR1020197037754A patent/KR20200010430A/ko not_active Application Discontinuation
- 2018-05-23 JP JP2019564917A patent/JP2020522473A/ja active Pending
- 2018-05-23 US US16/615,261 patent/US20200157227A1/en active Pending
- 2018-05-23 EP EP18806934.8A patent/EP3630169A4/en active Pending
- 2018-05-23 BR BR112019024632-0A patent/BR112019024632A2/pt unknown
- 2018-05-23 WO PCT/US2018/034223 patent/WO2018217947A1/en unknown
- 2018-05-23 AU AU2018271930A patent/AU2018271930A1/en active Pending
- 2018-05-23 RU RU2019142715A patent/RU2019142715A/ru unknown
-
2019
- 2019-11-20 IL IL270803A patent/IL270803A/en unknown
-
2023
- 2023-10-03 JP JP2023172090A patent/JP2024012297A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011506406A (ja) * | 2007-12-14 | 2011-03-03 | ノボ・ノルデイスク・エー/エス | ヒトnkg2dに対する抗体とその使用 |
JP2013500721A (ja) * | 2009-07-29 | 2013-01-10 | アボット・ラボラトリーズ | 二重可変ドメイン免疫グロブリンおよびその使用 |
WO2015197598A2 (en) * | 2014-06-27 | 2015-12-30 | Innate Pharma | Multispecific antigen binding proteins |
WO2016207273A2 (en) * | 2015-06-23 | 2016-12-29 | Innate Pharma | Multispecific antigen binding proteins |
Non-Patent Citations (1)
Title |
---|
ファルマシア, vol. 51, no. 5, JPN6021048876, 2015, pages 424 - 428, ISSN: 0005027314 * |
Also Published As
Publication number | Publication date |
---|---|
CA3064714A1 (en) | 2018-11-29 |
CN111278455A (zh) | 2020-06-12 |
WO2018217947A1 (en) | 2018-11-29 |
RU2019142715A (ru) | 2021-06-23 |
RU2019142715A3 (ja) | 2021-09-24 |
JP2024012297A (ja) | 2024-01-30 |
EP3630169A4 (en) | 2021-04-21 |
EP3630169A1 (en) | 2020-04-08 |
US20200157227A1 (en) | 2020-05-21 |
AU2018271930A1 (en) | 2019-12-12 |
IL270803A (en) | 2020-01-30 |
MX2019014000A (es) | 2020-07-29 |
BR112019024632A2 (pt) | 2020-06-16 |
KR20200010430A (ko) | 2020-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7187518B2 (ja) | Caix、ano1、メソテリン、trop2またはクローディン-18.2を標的にする多重特異性結合タンパク質 | |
JP7431392B2 (ja) | NKG2D、CD16およびNectin4に結合するタンパク質 | |
US20210261668A1 (en) | Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1 | |
JP7257323B2 (ja) | Bcma、nkg2d及びcd16と結合するタンパク質 | |
JP2020521448A (ja) | Nkg2d、cd16、およびror1またはror2に結合するタンパク質 | |
JP2024024048A (ja) | Her2、NKG2DおよびCD16に結合するタンパク質 | |
US20200277384A1 (en) | Proteins binding nkg2d, cd16, and c-type lectin-like molecule-1 (cll-1) | |
JP2024012297A (ja) | Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 | |
JP2023052214A (ja) | Cd33、nkg2d及びcd16と結合するタンパク質 | |
JP2023030174A (ja) | Nkg2d、cd16、および腫瘍関連抗原に結合するタンパク質 | |
US20200165344A1 (en) | Proteins binding nkg2d, cd16 and flt3 | |
JP2022105121A (ja) | Psma、nkg2dおよびcd16に結合するタンパク質 | |
JP2020510644A (ja) | Gd2、nkg2dおよびcd16に結合するタンパク質 | |
US20200002436A1 (en) | Proteins binding cd123, nkg2d and cd16 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210521 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210521 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230104 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230621 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230825 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20230825 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20230905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20230825 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240109 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240502 |